Spruce Biosciences Inc

SPRB

104.940USD

+0.190+0.18%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

Spruce Biosciences Inc's Score

Industry at a Glance

Industry Ranking

214 / 407

Overall Ranking

385 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

132.000

Target Price

+26.01%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Spruce Biosciences Inc Highlights

StrengthsRisks

Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare endocrine disorders with significant unmet medical needs. The Company is initially developing its wholly owned product candidate, Tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). It is also developing Tildacerfont for females suffering from polycystic ovary syndrome (PCOS). It has initiated CAHmelia-203, a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with classic CAH with elevated levels of androstenedione (A4) at baseline. It has also initiated CAHmelia-204, a second Phase IIb clinical trial in adult patients with classic CAH on supraphysiologic doses of glucocorticoids with normal or near normal levels of A4 at baseline focused on glucocorticoid reduction. The Company also investigates tildacerfont for the treatment of classic CAH in children.

Growing

The company is in a growing phase, with the latest annual income totaling USD 4.91M.

Overvalued

The company’s latest PE is -0.05, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 118.52K shares, decreasing 78.61% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 0.00 shares of this stock.

The company's current financial score is 8.26, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 77.49%.

Score

Industry at a Glance

Previous score

8.26

Change

0



Financials

9.57

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

9.61

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.13

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

6.99

Key Metrics

Free cash flow

No Data

There is no valuation score for this company; the Biotechnology & Medical Research industry's average is 7.05. Its current P/E ratio is -0.05, which is -92.56% below the recent high of -0.00 and -378.47% above the recent low of -0.24.

Score

Industry at a Glance

Previous score

0.00

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 214/407

No Data

The company’s current earnings forecast score is 7.00, which is lower than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Spruce Biosciences Inc is 132.00, with a high of 254.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

7.00

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 5.77, which is lower than the Biotechnology & Medical Research industry's average of 6.41. Sideways: Currently, the stock price is trading between the resistance level at 169.43 and the support level at 70.23, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.00

Change

-0.23

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated: 2025-11-04

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Ikarian Capital LLC

13.33K

--

Armistice Capital LLC

28.92K

--

HealthCap AB

39.70K

--

RiverVest Venture Partners, LLC

15.58K

-60.20%

Acadian Asset Management LLC

13.94K

--

Szwarcberg (Javier B M.D.)

6.23K

--

Gharib Samir M

4.67K

--

Charlton (Ralph William III)

2.15K

--



1

2



There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.47. The company's beta value is 3.49. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Spruce Biosciences Inc

SPRB

4.92 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

CytomX Therapeutics Inc

CTMX

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Insmed Inc

INSM

8.47 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Amicus Therapeutics Inc

FOLD

8.46 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.36 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment